GeneOne Life Science, Inc. (011000) Price & Analysis

― Followers

011000 Stock Chart & Stats

₩2670.00

₩0.00(0.00%)

Aug 18, 2026

―

Day’s Range― - ―

52-Week Range₩2,600.00 - ₩13,425.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)158.84K

Market Cap

₩48.51B

Enterprise Value₩76.53K

Total Cash (Recent Filing)₩6.82B

Total Debt (Recent Filing)₩34.15B

Price to Earnings (P/E)―

Beta0.21

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-11847.90

Shares Outstanding18,176,582

10 Day Avg. Volume0

30 Day Avg. Volume158,844

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)0.82

Price to Sales (P/S)1.40

P/FCF Ratio-2.02

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

011000 FAQ

What was GeneOne Life Science, Inc.’s price range in the past 12 months?

GeneOne Life Science, Inc. lowest stock price was ₩2600.00 and its highest was ₩13425.00 in the past 12 months.

What is GeneOne Life Science, Inc.’s market cap?

GeneOne Life Science, Inc.’s market cap is ₩48.51B.

When is GeneOne Life Science, Inc.’s upcoming earnings report date?

GeneOne Life Science, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 91 days.

How were GeneOne Life Science, Inc.’s earnings last quarter?

GeneOne Life Science, Inc. released its earnings results on Aug 14, 2026. The company reported -₩1044.903 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is GeneOne Life Science, Inc. overvalued?

According to Wall Street analysts GeneOne Life Science, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does GeneOne Life Science, Inc. pay dividends?

GeneOne Life Science, Inc. does not currently pay dividends.

What is GeneOne Life Science, Inc.’s EPS estimate?

GeneOne Life Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does GeneOne Life Science, Inc. have?

GeneOne Life Science, Inc. has 18,176,582 shares outstanding.

What happened to GeneOne Life Science, Inc.’s price movement after its last earnings report?

GeneOne Life Science, Inc. reported an EPS of -₩1044.903 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of GeneOne Life Science, Inc.?

Currently, no hedge funds are holding shares in KR:011000

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

GeneOne Life Science, Inc.

GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several candidates: GLS-1027 is in Phase I for nephropathy and inflammatory conditions, and also in Phase II trials for COVID-19. Similarly, GLS-1200 is being tested in Phase II for both Rhinosinusitis and COVID-19. Other compounds under development include GLS-3000 and GLS-5310 for SARS-CoV-2, GLS-5100 targeting VZV-Shingles, and GLS-5140 for SFTS. The company is also advancing GLS-5300 in Phase II for MERS, GLS-5700 in Phase I for Zika, and GLS-6150 in Phase I for hepatitis C, alongside GLS-6100 which is in a pre-clinical stage for hepatitis C. Additionally, through its subsidiary VGXI, Inc., GeneOne Life Science offers contract manufacturing services for nucleic acid-based products, specifically DNA plasmids and mRNA, under cGMP standards. The company adopted its current name in April 2014, having previously been known as VGX International Inc.